SUBSCRIBE
SUBSCRIBE
News   Drug Development

ZIOPHARM, Inc. Commences Treatment of First Patients in Two Separate Phase I/II Combination Studies of Both Indibulin and Palifosfamide

February 4, 2008 | 
1 min read

NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today that dosing of the first patient took place in two separate new studies, including:

Clinical research Phase I
MORE ON THIS TOPIC
Roche's signage at its office in France
Parkinson’s disease
Roche’s Prothena-Partnered Parkinson’s Drug Fails Mid-Stage Trial
December 19, 2024
 · 
1 min read
 · 
Annalee Armstrong
Entrance to Vertex's office in Boston, Massachusetts
Pain
Vertex Dips on Mixed Phase II Data for Non-Opioid Pain Therapy
December 19, 2024
 · 
2 min read
 · 
Tristan Manalac
Novo Nordisk advertising flags and logo on facade
Deals
Novo Adds Novel Approach to Cardiometabolic Pipeline With Photys Collab
December 18, 2024
 · 
1 min read
 · 
Kate Goodwin
Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.
Cardiovascular disease
Tenaya Stock Crashes as Cardio Gene Therapy Delivers Underwhelming Early-Stage Data
December 18, 2024
 · 
2 min read
 · 
Tristan Manalac